Immunome, Inc.

Equities

IMNM

US45257U1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
13.82 ^USD	+0.66%		-9.55%	+29.16%

Apr. 25	Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	CI
Apr. 15	Guggenheim Starts Immunome With Buy Rating, $35 Price Target	MT

Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 04:06 pm EDT

Immunome, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 106.81 million compared to USD 36.9 million a year ago. Basic loss per share from continuing operations was USD 5.38 compared to USD 3.09 a year ago.

Latest news about Immunome, Inc.

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	Apr. 25	CI
Guggenheim Starts Immunome With Buy Rating, $35 Price Target	Apr. 15	MT
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating	Apr. 01	MT
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	Mar. 24	CI
Immunome Closes $230 Million Public Offering	Feb. 16	MT
Immunome Prices Stock Offering at $20 a Share	Feb. 14	MT
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating	Feb. 07	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 06	MT
Top Midday Gainers	Feb. 06	MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	Feb. 06	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	Feb. 05	CI
Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations	Feb. 01	CI
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	Jan. 23	MT
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	Jan. 08	CI
Immunome Appoints Phil Roberts as Chief Technical Officer	Jan. 04	MT
Immunome Appoints Phil Roberts as Chief Technical Officer	Jan. 04	CI
Immunome, Inc. Announces Board Changes	Jan. 02	CI
Immunome, Inc. Announces Executive Changes, Effective January 2, 2024	Dec. 29	CI
Immunome, Inc. Announces Chief Financial Officer Changes, Effective January 2, 2024	Dec. 29	CI
Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	Dec. 26	MT
Immunome, Inc. entered into an agreement to acquire Substantially all Assets of Atreca, Inc. for $12.5 million.	Dec. 25	CI
Immunome Shares Rise After Wedbush Starts Coverage With outperform Rating	Dec. 19	MT
Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies	Dec. 19	MT
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI

Chart Immunome, Inc.

Duration

Period

More charts

Company Profile

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Immunome, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.82 USD

Average target price

35.33 USD

Spread / Average Target

+155.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNOME, INC.	+29.16%	828M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.46%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.58%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs